Felipe Magalhães Furtado

Felipe Magalhães Furtado

Auto-generated profile, based on publicly available information

Felipe Magalhães Furtado

Sabin Diagnostico e Saude Brasilia Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2020 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
MIMaura Rosane Valério Ikoma-Colturato
Maura Rosane Valério Ikoma-Colturato
MBMiriam P. Beltrame
Miriam P. Beltrame
FFFelipe M. Furtado
Felipe M. Furtado
GPGlicinia Pimenta
Glicinia Pimenta
ECElaine Sobral da Costa
Elaine Sobral da Costa
MYMihoko Yamamoto
Mihoko Yamamoto
The minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reliable results through well standardized technical processes by establishing rigorous operating procedures. Our goal is to propose a monoclonal antibody (MoAb) panel for MRD detection in ALL and provide recommendations intended for flow cytometry laboratories that work on 4-color flow cytometry platforms. The document includes pre-analytical and analytical procedures, quality control assurance, technical procedures, as well as the information that needs to be included in the reports for clinicians.

8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
MPMariana Pinto Pereira
Mariana Pinto Pereira
MIMaura Rosane Valério Ikoma-Colturato
Maura Rosane Valério Ikoma-Colturato
VFVaneuza ARAUJO MOREIRA Funke
Vaneuza ARAUJO MOREIRA Funke
BPBeatriz Stela Gomes de Souza Pitombeira
Beatriz Stela Gomes de Souza Pitombeira
EPEduardo José de Alencar Paton
Eduardo José de Alencar Paton
LSLucia Silla
Lucia Silla
This document updates the 2023 Brazilian Society of Cell Therapy and Bone Marrow Transplantation (SBTMO) consensus on allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML), incorporating the 2022 and 2024 European LeukemiaNet (ELN) risk classifications, the 2025 ELN-DAVID measurable residual disease (MRD) recommendations, recent induction trials, and the 2025 European Society for Blood and Marrow Transplantation (EBMT) transplant indications. MRD monitoring, assessed by quantitative polymerase chain reaaction, next-generation sequencing, or multiparameter flow cytometry, now guides transplant timing alongside ELN risk category, refining decisions in intermediate-risk patients and informing pre- and post-transplant management. Allogeneic HSCT remains indicated for adverse-risk AML and second complete remission regardless of MRD status, while favorable-risk patients generally avoid transplant unless MRD persists after consolidation. For elderly patients, chronological age alone should not exclude HSCT candidacy; comprehensive geriatric assessment and alternative donor sources have expanded access, supported by Brazilian regulatory changes raising the eligibility age to 75. Conditioning strategy, graft-versus-host disease prophylaxis with post-transplant cyclophosphamide, stem cell source selection, and donor immunogenetic screening are addressed, alongside emerging post-transplant maintenance therapies for high-risk molecular subgroups. Novel cellular therapies— CAR-T and CAR-NK cells—remain investigational, limited by antigen escape and short persistence, requiring consolidation with allogeneic HSCT. This consensus provides evidence-graded recommendations to standardize transplant decisionmaking for AML across Brazilian centers, reflecting the rapidly evolving therapeutic and diagnostic landscape.

3 November 2026 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
FFFelipe Magalhães Furtado
Felipe Magalhães Furtado
FRFernanda de Oliveira Resende
Fernanda de Oliveira Resende
CNCamila Santos Nobre
Camila Santos Nobre
ADAlan Carvalho Dias
Alan Carvalho Dias
APAndré Luiz Pinto
André Luiz Pinto
AFAdamara Felício
Adamara Felício
The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on detecting cells deficient in GPI‐anchored proteins and is currently based on manual, time‐consuming interpretation requiring specialized expertise. This study aimed to develop machine learning models to identify PNH clones in granulocytes and monocytes using flow cytometry data containing information on cell size, complexity, and expression of FLAER, CD15, CD45, CD64, and CD157. For training, 20 normal and 20 PNH samples were randomly selected; normal samples were used in full, whereas only PNH cells were retained from PNH samples. For analytical validation, 22 normal and 18 PNH samples were analyzed in their entirety. Samples were processed through a preprocessing pipeline and split into training (12 normal, 12 PNH), validation (4 normal, 4 PNH), and test (4 normal, 4 PNH) datasets. Two supervised models were developed: a Random Forest (RF) and an Artificial Neural Network (ANN). Validation samples underwent the same preprocessing, except for concatenation. Both models achieved specificity close to 100%, accuracy >93%, ROC‐AUC >0.99, and PR‐AUC >0.98; the ANN showed higher sensitivity (0.85 vs. 0.78) and F1‐score (0.92 vs. 0.87). In qualitative analysis, RF and ANN achieved 100% and 45% agreement with manual analysis, respectively, and quantitative analysis confirmed statistical equivalence between RF and manual results. RF repeatability was confirmed by identical triplicate results in 10 samples. In spiking experiments, RF identified >50 PNH cells in all samples spiked with 200 or 100 cells, in 3 of 5 samples spiked with 50 cells, and in none spiked with 25 cells. These results indicate that the RF model shows promise for PNH analysis; however, clinical implementation will require integration into immunophenotyping software and post‐deployment performance monitoring.